“The world is a funny place; we know the problem with antimicrobial resistance and we know we have the tools to address it, across different disciplines, fields & industries, but it takes an economist, Jim O’Neill, to come in, shake us all up and tell us to work together.
We in the healthcare industry have a responsibility to recognise that the solution is in collaboration. We must forge new alliances and form new business models to bring about exciting new technologies, therapeutics, clinical practices and data sharing.
This will accelerate R&D and ultimately provide solutions to solve, or at least manage the problem of AMR. If we don’t, tens of millions of people could die. What more of an incentive do we need?”
These words come from our CSO, Jonathan O’Halloran, following the Wellcome Trust’s antimicrobial resistance review meeting. He was there to discuss the significant impact that accessible drug resistance testing could have, something which QuantuMDx is working to deliver with its low cost handheld DNA analyser.